Prostatype Genomics Balance Sheet Health
Financial Health criteria checks 4/6
Prostatype Genomics has a total shareholder equity of SEK24.7M and total debt of SEK11.7M, which brings its debt-to-equity ratio to 47.3%. Its total assets and total liabilities are SEK49.2M and SEK24.5M respectively.
Key information
47.3%
Debt to equity ratio
kr11.67m
Debt
| Interest coverage ratio | n/a |
| Cash | kr2.68m |
| Equity | kr24.67m |
| Total liabilities | kr24.55m |
| Total assets | kr49.22m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: PROGEN's short term assets (SEK25.9M) exceed its short term liabilities (SEK24.5M).
Long Term Liabilities: PROGEN's short term assets (SEK25.9M) exceed its long term liabilities (SEK66.0K).
Debt to Equity History and Analysis
Debt Level: PROGEN's net debt to equity ratio (36.4%) is considered satisfactory.
Reducing Debt: PROGEN's debt to equity ratio has reduced from 110.9% to 47.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PROGEN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: PROGEN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 25.3% each year